Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Bringing Advanced Therapies for Parkinson's Disease to the Clinic : The Scientist's Perspective

Tomishima, Mark and Kirkeby, Agnete LU (2021) In Journal of Parkinson's Disease 11(s2). p.135-140
Abstract

After many years of preclinical development, cell and gene therapies have advanced from research tools in the lab to clinical-grade products for patients, and today they constitute more than a quarter of all new Phase I clinical trials for Parkinson's disease. Whereas efficacy has been convincingly proven for many of these products in preclinical models, the field is now entering a new phase where the functionality and safety of these products will need to stand the test in clinical trials. If successful, these new products can have the potential to provide patients with a one-time administered treatment which may alleviate them from daily symptomatic dopaminergic medication.

Please use this url to cite or link to this publication:
author
and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
ATMP, clinical trial, dopaminergic neurons, regenerative therapy, stem cells, transplantation
in
Journal of Parkinson's Disease
volume
11
issue
s2
pages
135 - 140
publisher
IOS Press
external identifiers
  • scopus:85116015714
  • pmid:34250954
ISSN
1877-7171
DOI
10.3233/jpd-212685
language
English
LU publication?
yes
additional info
Publisher Copyright: © 2021 - The authors. Published by IOS Press.
id
61b97542-cb89-4ec1-9a46-96eb786f8db1
date added to LUP
2021-10-25 10:52:33
date last changed
2024-07-13 21:24:18
@article{61b97542-cb89-4ec1-9a46-96eb786f8db1,
  abstract     = {{<p>After many years of preclinical development, cell and gene therapies have advanced from research tools in the lab to clinical-grade products for patients, and today they constitute more than a quarter of all new Phase I clinical trials for Parkinson's disease. Whereas efficacy has been convincingly proven for many of these products in preclinical models, the field is now entering a new phase where the functionality and safety of these products will need to stand the test in clinical trials. If successful, these new products can have the potential to provide patients with a one-time administered treatment which may alleviate them from daily symptomatic dopaminergic medication.</p>}},
  author       = {{Tomishima, Mark and Kirkeby, Agnete}},
  issn         = {{1877-7171}},
  keywords     = {{ATMP; clinical trial; dopaminergic neurons; regenerative therapy; stem cells; transplantation}},
  language     = {{eng}},
  number       = {{s2}},
  pages        = {{135--140}},
  publisher    = {{IOS Press}},
  series       = {{Journal of Parkinson's Disease}},
  title        = {{Bringing Advanced Therapies for Parkinson's Disease to the Clinic : The Scientist's Perspective}},
  url          = {{http://dx.doi.org/10.3233/jpd-212685}},
  doi          = {{10.3233/jpd-212685}},
  volume       = {{11}},
  year         = {{2021}},
}